BARBARA W. RICHARD, M.A.; LOUIS LASAGNA, M.D.
In 1984, both the United Kingdom and the United States received recommendations from panels of experts specifically convened to consider the merits of Depo-Provera (depot medroxyprogesterone acetate [DMPA]) as a long-term contraceptive agent. This study compares the final reports written by these panels. We explore why, despite access to essentially the same data, the U.K. panel recommended marketing approval but the U.S. Public Board of Inquiry did not. We conclude that differing national policies helped shape the interpretation of the data and thus the divergent outcomes.
RICHARD BW, LASAGNA L. Drug Regulation in the United States and the United Kingdom: The Depo-Provera Story. Ann Intern Med. ;106:886–891. doi: 10.7326/0003-4819-106-6-886
Download citation file:
Published: Ann Intern Med. 1987;106(6):886-891.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use